161 related articles for article (PubMed ID: 37808997)
41. Prevalence, treatment, and outcomes of renal conditions in pediatric sickle cell disease.
Stallworth JR; Tripathi A; Jerrell JM
South Med J; 2011 Nov; 104(11):752-6. PubMed ID: 22024785
[TBL] [Abstract][Full Text] [Related]
42. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.
Ramsey SD; Bender MA; Li L; Johnson KM; Jiao B; Devine B; Basu A
PLoS One; 2022; 17(11):e0278137. PubMed ID: 36445914
[TBL] [Abstract][Full Text] [Related]
43. Increased Patient Activation Is Associated with Fewer Emergency Room Visits and Hospitalizations for Pain in Adults with Sickle Cell Disease.
Cronin RM; Dorner TL; Utrankar A; Allen W; Rodeghier M; Kassim AA; Jackson GP; DeBaun MR
Pain Med; 2019 Aug; 20(8):1464-1471. PubMed ID: 30329108
[TBL] [Abstract][Full Text] [Related]
44. Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.
Zhou J; Han J; Nutescu EA; Gordeuk VR; Saraf SL; Calip GS
Br J Haematol; 2018 Jul; 182(2):259-270. PubMed ID: 29767446
[TBL] [Abstract][Full Text] [Related]
45. Descriptive analysis of sickle cell patients living in France: The PHEDRE cross-sectional study.
Gerardin M; Rousselet M; Couec ML; Masseau A; Guerlais M; Authier N; Deheul S; Roussin A; Micallef J; Djezzar S; ; Feuillet F; Jolliet P; Victorri-Vigneau C
PLoS One; 2021; 16(3):e0248649. PubMed ID: 33735176
[TBL] [Abstract][Full Text] [Related]
46. Factors influencing utilization of hospital services by adult sickle cell disease patients: a systematic review.
Benenson I; Jadotte Y; Echevarria M
JBI Database System Rev Implement Rep; 2017 Mar; 15(3):765-808. PubMed ID: 28267033
[TBL] [Abstract][Full Text] [Related]
47. A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11.
Pizzo E; Laverty AA; Phekoo KJ; AlJuburi G; Green SA; Bell D; Majeed A
J Public Health (Oxf); 2015 Sep; 37(3):529-39. PubMed ID: 24796312
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature.
Hoogenboom WS; Alamuri TT; McMahon DM; Balanchivadze N; Dabak V; Mitchell WB; Morrone KB; Manwani D; Duong TQ
Blood Rev; 2022 May; 53():100911. PubMed ID: 34838342
[TBL] [Abstract][Full Text] [Related]
49. Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.
Jordan L; Adams-Graves P; Kanter-Washko J; Oneal PA; Sasane M; Vekeman F; Bieri C; Magestro M; Marcellari A; Duh MS
Curr Med Res Opin; 2015 Mar; 31(3):513-23. PubMed ID: 25495135
[TBL] [Abstract][Full Text] [Related]
50. Description of criteria for near miss in high-complexity obstetric population with sickle cell anemia: an observational study.
Burgos Luna JM; Páez Rúa DM; Ruiz Ordoñez I; Fernández PA; Escobar Vidarte MF
J Matern Fetal Neonatal Med; 2020 Mar; 33(6):941-946. PubMed ID: 30231783
[No Abstract] [Full Text] [Related]
51. Sickle cell disease and coronavirus disease-2019 (COVID-19) infection: a single-center experience.
Devarashetty SP; Grewal US; Le Blanc K; Walton J; Jones T; Shi R; Master SR; Mansour RP; Ramadas P
Postgrad Med J; 2023 Aug; 99(1175):1008-1012. PubMed ID: 37399057
[TBL] [Abstract][Full Text] [Related]
52. Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.
Emery C; Torreton E; Briere JB; Evers T; Fagnani F
J Med Econ; 2020 May; 23(5):513-520. PubMed ID: 31928390
[No Abstract] [Full Text] [Related]
53. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes.
Bou-Maroun LM; Meta F; Hanba CJ; Campbell AD; Yanik GA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28801954
[TBL] [Abstract][Full Text] [Related]
54. Comparisons of Severe Maternal Morbidity and Other Adverse Pregnancy Outcomes in Pregnant People With Sickle Cell Disease vs Anemia.
Early ML; Eke AC; Gemmill A; Lanzkron S; Pecker LH
JAMA Netw Open; 2023 Feb; 6(2):e2254545. PubMed ID: 36729453
[TBL] [Abstract][Full Text] [Related]
55. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
56. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
Akar NA; Adekile A
Med Princ Pract; 2008; 17(5):404-8. PubMed ID: 18685282
[TBL] [Abstract][Full Text] [Related]
57. Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease.
Lubeck D; Agodoa I; Bhakta N; Danese M; Pappu K; Howard R; Gleeson M; Halperin M; Lanzkron S
JAMA Netw Open; 2019 Nov; 2(11):e1915374. PubMed ID: 31730182
[TBL] [Abstract][Full Text] [Related]
58. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
59. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
[TBL] [Abstract][Full Text] [Related]
60. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
